Indication
In combination with tremelimumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma
Medicine details
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
- SMC2857
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Publication due date:
- 10 November 2025
- SMC meeting date:
- 07 October 2025
- Patient group submission deadline:
- TBC